Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and Aims: Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies. Approach and Results: We conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results. Conclusions: Age rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748 · cited 2×
“One possible explanation of our findings is that although microvascular complications of T2D can develop in a few years, the progression of liver disease typically develops over decades.[20] Thus, the change in incidence rate may occur after a longer period of diabetes than what was captured in the current study.”
BackgroundResultVilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806
Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209 · cited 1×
“Advanced age has been consistently shown to be an important risk factor of advanced liver fibrosis[16] and HCC in patients with NASH cirrhosis.[17] The annual incidence rate of liver- related events between the population aged 40 and 50 years is much lower than aged older than 50 years.”
BackgroundRepeated FIB-4 measurements can help identify individuals at risk of severe liver disease
Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.007 · Cited by 199
Simon, T. G., King, L. Y., Chong, D. Q., Nguyen, L. H., Ma, Y., VoPham, T., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., et al. (2018) · Hepatology · doi:10.1002/hep.29660 · Cited by 160
Zhang, X., Wong, G. L., Yip, T. C., Tse, Y., Liang, L. Y., Hui, V. W., Lin, H., Li, G., Lai, J. C., Chan, H. L., et al. (2022) · Hepatology · doi:10.1002/hep.32294 · Cited by 93
Self-citation
Cited by
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Self-citationMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Self-citationChen, V. L., Oliveri, A., Miller, M. J., Wijarnpreecha, K., Du, X., Chen, Y., Cushing, K. C., Lok, A. S., & Speliotes, E. K. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.040 · Cited by 108
Zhang, X., Yip, T. C.-F., Wong, G. L.-H., Leow, W.-X., Liang, L. Y., Lim, L.-L., Li, G., Ibrahim, L., Lin, H., Lai, J. C. T., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330269 · Cited by 55
“In contrast, referral was not prompted by patient age (a risk factor for advanced liver disease), 27 28 anthropometric factors, glycaemic control, elevated liver enzymes, diagnosis of viral hepatitis or thrombocytopenia (a proxy of cirrhosis).”
Self-citationAge and the relative importance of liver-related deaths in nonalcoholic fatty liver disease
Lin, H., Yip, T. C., Zhang, X., Li, G., Tse, Y., Hui, V. W., Liang, L. Y., Lai, J. C., Chan, S. L., Chan, H. L., et al. (2023) · Hepatology · doi:10.1002/hep.32633 · Cited by 52
Self-citation
Metadata
- Authors
- Zhang, X., Wong, G. L., Yip, T. C., Cheung, J. T. K., Tse, Y., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P., & Wong, V. W.
- Venue
- Hepatology
- Published
- 2022-04-07
- Volume
- 76
- Issue
- 5
- Pages
- 1409-1422
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W4221136515
- Cited by
- 56
- References
- 8
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1002/hep.32476
- The paper
- Zhang, X., Wong, G. L., Yip, T. C., Cheung, J. T. K., Tse, Y., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P., & Wong, V. W. (2022). Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology. https://doi.org/10.1002/hep.32476
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.